New drug combo aims to Re-Sensitize tough thyroid cancers to standard treatment
NCT ID NCT02152995
Summary
This study is testing if adding an oral drug called trametinib can make radioactive iodine treatment work again for people with advanced thyroid cancer that has spread or come back and no longer responds to iodine. The goal is to see if trametinib helps the cancer absorb more iodine, potentially stopping or slowing its growth. The study enrolled 34 adults with specific genetic types of this hard-to-treat cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.